Objectives Chorea, characterised by involuntary, irregular movements, is a rare neurological manifestation of antiphospholipid syndrome (APS). The specific clinical features remain unclear. This study ...

Neurocrine Biosciences' stock dropped after a lackluster trial. Click here to read more about the potential for this biotech ...

Chorea-acanthocytosis is a rare genetic disorder of the nervous system. It causes involuntary jerks and twitches in the muscles, known as chorea, and star-shaped red blood cells, known as ...

Tavapadon, an investigational D1/D5 dopamine receptor partial agonist, improved scores on the combined part II and III ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX), Monday announced interim data of KINECT-HD2 study of Ingrezza capsules for the long-term treatment of adults with chorea associated with Huntington's ...

This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat tardive dyskinesia and chorea caused by Huntington’s disease. Ingrezza can cause side effects that range from mild to serious.

Mid-cap stocks are presenting a golden opportunity for investors, offering a compelling combination of stability and ...

Huntington’s chorea: Initially 40mg once daily, then increase in 20mg increments every 2 weeks up to 80mg once daily. Both: may consider 40mg or 60mg once daily based on response and tolerability.

TBZ is effective and safe and unanimously recommended to the FDA approval of TBZ (Xenazine) for the treatment of chorea associated with Huntington's disease. Although not approved by the FDA yet, TBZ ...

Few people would likely disagree that, once we learn how, genetically preventing tragic diseases such as Huntington's chorea would be acceptable, if not prescribed. NOVA: Is it ethical to alter ...

The birth of Dolly, the first mammal cloned from the cell of an adult animal, sent intellectual and emotional shockwaves around the world when it was reported in early 1997. What's next ...